Cancer Biology & Therapy
Leading citation impact metric from Clarivate Journal Citation Reports
101 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 3.00đ | WoS Q1 có IF ≥ 5.0(IF: 5.7) | 🔵 Computed |
| 2025 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 4.6) | 🔵 Computed |
| 2024 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 4.4) | 🔵 Computed |
| 2023 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.6) | 🔵 Computed |
| 2022 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 4.875) | 🔵 Computed |
| 2021 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 4.742) | 🔵 Computed |
| 2020 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.659) | 🔵 Computed |
| 2019 | 2.00đ | WoS Q1(IF: 2.879) | 🔵 Computed |
| 2018 | 2.50đ | WoS Q1 có IF ≥ 3.0(IF: 3.373) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Measures cumulative publication volume and citation impact.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
ONCOLOGY | JCRSCIE | 72/333 | Q1 |
ONCOLOGY | JCISCIE | 65/333 | Q1 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 51 | 3 |
| 2025 | 4.6 | 88 | 339 |
| 2024 | 4.4 | 115 | 1,322 |
| 2023 | 3.6 | 88 | 1,228 |
| 2022 | 4.875 | 65 | 1,434 |
| 2021 | 4.742 | 57 | 1,011 |
| 2020 | 3.659 | 117 | 2,170 |
| 2019 | 2.879 | 118 | 5,524 |
| 2018 | 3.373 | 192 | 5,662 |
| 2017 | — | 141 | 4,422 |
| 2016 | — | 142 | 4,574 |
| 2015 | — | 221 | 8,364 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Cancer Biology & Therapy
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics